Protara Therapeutics, Inc. advances clinical-stage therapies for cancer and rare diseases, with its lead program TARA-002, an investigational cell therapy based on the immunopotentiator OK-432 approved in Japan and Taiwan. TARA-002 is being evaluated for non-muscle invasive bladder cancer and lymphatic malformations. The company additionally develops intravenous choline chloride as a phospholipid substrate replacement for patients who rely on parenteral nutrition and cannot meet their choline requirements orally.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -11.9 | — |
| Q2 2025 | 0 | — | -15 | — |
| Q3 2025 | 0 | — | -13.3 | — |
| Q4 2025 | 0 | — | -17.3 | — |
| Q1 2026 | 0 | — | -17.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Atrium Therapeutics, Inc. (RNA), Crown Reserve Acquisition Corp. I (CRAC), FB Bancorp, Inc. (FBLA), XChange TEC.INC (XHG), AstroNova, Inc. (ALOT), Mercator Acquisition Corp. (MRCO)